Summary
A prospective cohort study was conducted at the Indus Hospital Karachi, Pakistan between March and June 2020 to describe the determinants of mortality among hospitalized COVID-19 patients. 186 adult patients were enrolled and all-cause mortality was found to be 36% (67/186). Those who died were older and more likely to be males (p<0.05). Temperature and respiratory rate were higher among non-survivors while Oxygen saturation was lower (p<0.05). Serum CRP, D-dimer and IL-6 were higher while SpO2 was lower on admission among non-survivors (p<0.05). Non-survivors had higher SOFA and CURB-65 scores while thrombocytopenia, lymphopenia and severe ARDS was more prevalent among them (p<0.05). Use of non-invasive ventilation in emergency room, ICU admission and invasive ventilation were associated with mortality in our cohort (p<0.05). Length of hospital stay and days of intubation were longer in non-survivors (p<0.05). Use of azithromycin, hydroxychloroquine, steroids, tocilizumab, antibiotics, IVIG or anticoagulation showed no mortality benefit (p>0.05). Multivariable logistic regression showed that age > 60 years, oxygen saturation <93% on admission, pro-calcitonin > 2 ng/ml, unit rise in temperature and SOFA score, ICU admission and sepsis during hospital stay were associated with higher odds of mortality. Larger prospective studies are needed to further strengthen these findings.
Key Findings
Age greater than 60 years is associated with in-hospital mortality among COVID-19 patients
Oxygen saturation less than 93% and ICU admission are associated with higher odds of mortality
Inflammatory markers including CRP, Ferritin and IL-6 were significantly higher among non-survivors
Serum pro-calcitonin greater than 2 ng/ml and sepsis during hospital stay are associated with higher odds of mortality among COVID-19 patients
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the IRB (approval number "IRD_IRB_2020_04_002") under IRD which is Interactive Research & Development (IORG0004336) registered with the U.S. Department of Health and Human Services (DHHS) Office for Human Research Protections organization with an IRB# 00005148 (effective through Nov 19, 2023). IRD-IRB has federal wide assurance (FWA) for the protection of Human Subjects for International (non US) Institutions FWA00023738 expiration date Dec 18, 2025. In additions, IRD-IRB is the designated IRB for The Indus Hospital (FWA # 00016337) for the review and continuing oversight for all its human subject research vide an authorization agreement with IRD (Expires Dec 16, 2025).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
available on request
